CO-EXISTING HASHIMOTO'S THYROIDITIS DOES NOT AFFECT BONE METABOLISM IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM

Area of Science:

• Endocrinology
• Bone Metabolism
• Immunology

Background:

• Primary hyperparathyroidism (PHPT) is frequently observed alongside thyroid disorders, including Hashimoto's thyroiditis (HT).
• The impact of co-existing HT on bone metabolism in PHPT patients remains unclear.

Purpose of the Study:

• To investigate whether the presence of HT influences bone metabolism markers in patients diagnosed with PHPT.
• To explore the relationship between interleukin-17A and bone turnover in PHPT, with or without HT.

Main Methods:

• A comparative cross-sectional study involving 100 PHPT patients (50 with and 50 without HT) and two control groups.
• Measurement of serum calcium-phosphate metabolism markers, bone turnover markers (RANKL, Osteoprotegerin, β-CTX, Osteocalcin), and interleukin-17A.

Main Results:

• The prevalence of HT in PHPT patients (37.6%) was similar to the general population.
• No significant differences in bone metabolism markers or interleukin-17A were found between PHPT patients with and without HT.
• PHPT patients exhibited elevated levels of interleukin-17A, β-CTX, and Osteocalcin compared to controls.

Conclusions:

• Hashimoto's thyroiditis does not appear to have an additional effect on bone metabolism in patients with primary hyperparathyroidism.
• Elevated interleukin-17A levels in PHPT patients may indicate a role in parathyroid hormone-induced bone remodeling.